Deutsch English Français

Contact

EP3757106

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3757106

EP3757106 - CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 15.07.2022 Database last updated on 08.04.2026
Former	Examination is in progress Status updated on 12.11.2021
Former	Request for examination was made Status updated on 02.07.2021
Former	The application has been published Status updated on 27.11.2020
Most recent event Tooltip	15.07.2022	Application deemed to be withdrawn	published on 17.08.2022 [2022/33]
Applicant(s)	For all designated states Medivation Technologies LLC 235 East 42nd Street New York, NY 10017 / US
	[2021/13]
Former [2021/01]	For all designated states Medivation Technologies LLC 525 Market St., 28th Floor San Francisco, CA 94105 / US
Inventor(s)	01 / WANG, Bing 2041 Mandelay Place San Jose, CA 95138 / US
	02 / CHU, Daniel 3767 Benton Street Santa Clara, CA 95051 / US
	03 / LIU, Yongbu Building 6 998 Halei Road Pudong, Shanghai 201203 / CN
	04 / PENG, Shichun 144-102 2111 West Gaoke Road Pudong, Shanghai 200125 / CN
	[2021/01]
Representative(s)	Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
	[2021/01]
Application number, filing date	20175014.8	20.10.2011
	[2021/01]
Priority number, date	US201040547610P	21.10.2010 Original published format: US 40547610 P
	[2021/01]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP3757106
	Date:	30.12.2020
	Language:	EN
	[2020/53]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	12.11.2020
Classification	IPC:	C07D471/06, A61K31/5025, A61P35/00	[2021/01]
	CPC:	C07D471/06 (EP,KR,US); A61K31/5025 (KR); A61P35/00 (EP,KR); A61P35/02 (EP); C07B2200/13 (KR)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/31]
Former [2021/01]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Title	German:	KRISTALLINES (8S, 9R) -5-FLUOR-8- (4-FLUORPHENYL) -9- (1-METHYL-1H-1,2,4-TRIAZOL-5-YL) -8,9-DIHYDRO-2H-PYRIDO [4,3,2-DE] PHTALAZIN-3 (7H) -ON-TOSYLATSALZ	[2021/01]
	English:	CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT	[2021/01]
	French:	SEL TOSYLATE DE LA (8S,9R)-5-FLUORO-8-(4-FLUOROPHÉNYL)-9-(1-MÉTHYL-1H- 1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE CRISTALLIN	[2021/01]
Examination procedure	30.06.2021	Amendment by applicant (claims and/or description)
	30.06.2021	Examination requested [2021/31]
	30.06.2021	Date on which the examining division has become responsible
	11.11.2021	Despatch of a communication from the examining division (Time limit: M04)
	22.03.2022	Application deemed to be withdrawn, date of legal effect [2022/33]
	12.04.2022	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/33]
Parent application(s) Tooltip	EP11777005.7 / EP2630146
Fees paid	Renewal fee
	15.05.2020	Renewal fee patent year 03
	15.05.2020	Renewal fee patent year 04
	15.05.2020	Renewal fee patent year 05
	15.05.2020	Renewal fee patent year 06
	15.05.2020	Renewal fee patent year 07
	15.05.2020	Renewal fee patent year 08
	15.05.2020	Renewal fee patent year 09
	02.11.2020	Renewal fee patent year 10
	02.11.2021	Renewal fee patent year 11
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[IA] US2010035883 (WANG BING et al.)
		[IPA] WO2011097602 (BIOMARIN PHARM INC et al.)
	by applicant	US2010035883
		WO2011097602
		"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
		"Pharmaceutical Preformulation and Formulation", 2009, AMERICAN PHARMACEUTICAL ASSOCIATION
		"Handbook of Pharmaceutical Additives", 2007, GOWER PUBLISHING COMPANY
		"Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO.
		LEAFEBIGER: "Introduction to Pharmaceutical Dosage Forms", 1985, U.S. PHARMACOPEIA CONVENTION, INC.

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.